Skip to main content
. 2013 Oct 1;170(4):847–858. doi: 10.1111/bph.12317

Figure 4.

Figure 4

PI3K inhibitor and MAP kinase-ERK kinase (MEK) inhibitor attenuated simvastatin-induced PI3K-Akt-endothelial NOS (eNOS) and ERK1/2-ribosomal protein S6 kinase (RSK)-eNOS pathway activity. (A) Immunoblot showing P-AktS473 and P-eNOSS1177 protein levels after simvastatin treatment with the PI3K inhibitor LY294002. The elevated Akt and eNOS phosphorylation ratios observed with simvastatin treatment were reduced by LY294002 in the nucleus tractus solitarii (NTS). (B) Immunoblot showing P-ERK1/2T202/Y204, P-RSKT359/S363 and P-eNOSS1177 protein levels after simvastatin treatment with the MEK inhibitor PD98059. The elevated ERK1/2, RSK and eNOS phosphorylation ratios observed with simvastatin were reduced by PD98059 in the NTS. Values are shown as the mean ± SEM, n = 6. *P < 0.05 versus control group and #P < 0.05 versus simvastatin group.